Sign in
Taking people in United KingdomPhase 2/3

Dabrafenib and trametinib for rare cancers with a BRAF V600 mutation

Tests dabrafenib with trametinib in people whose cancer has a BRAF V600 mutation.

Key facts

Who runs it
Cancer Research UK
Where
Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Leicester, Liverpool, London, Manchester, Metropolitan Borough of Wirral, Newcastle, Oxford, Sheffield, Southampton, and Sutton, United KingdomSee the 27 sites
Trial code
Registry title
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Status
Recruiting
Phase
Phase 2/3
People taking part
30 people, planned
Started
1 Apr 2026
Expected to end
Oct 2029
Type of study
Interventional
Treatments tested
  • Dabrafenib
  • Trametinib
Record updated
17 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 1 year and older with a cancer that has a BRAF V600 gene change. It tests dabrafenib and trametinib together.

Age
1 year or older, and at least 8 kg (18 lb) in body weight.
Sex
All sexes can join.
Disease stage
Any cancer with a BRAF V600 change, including Langerhans cell histiocytosis. Some cancers with the BRAF V600E change in adults or children are not included (see exclusions).
Earlier treatment
Cannot have had dabrafenib with trametinib, or other BRAF and MEK inhibitors together, for the current cancer.
Biomarker or test result
A BRAF V600 alteration confirmed by a validated next-generation sequencing test.

Main reasons for not taking part

  • Colorectal cancer, unresectable or metastatic melanoma, or advanced non-small cell lung cancer with BRAF V600E in adults
  • Glioma with BRAF V600E in children and teenagers under 18 years
  • Pregnant or breastfeeding women, or those planning pregnancy during the trial
  • History of retinal vein occlusion, or known allergy to dabrafenib or trametinib
  • Recent serious heart or brain blood vessel disease, or active infection that could affect the trial

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Confirmed diagnosis of a malignancy harbouring an oncogenic alteration in BRAF V600, including Langerhans cell histiocytosis, using an analytically validated next-generation sequencing method
  • Patients ≥1 year old and ≥8 kg in body weight
  • Women of childbearing potential are eligible provided that they meet the following criteria:
  • Have a negative serum or urine pregnancy test before enrolment and
  • Agree to use one form of a non-hormonal highly effective contraception method (a method that can achieve a failure rate of <1% when used consistently and correctly; the requirement for non-hormonal method is because dabrafenib may decrease the efficacy of oral or any systemic hormonal contraceptives), such as: i. intrauterine device (IUD), ii. bilateral tubal occlusion, bilateral tubal ligation (at least six weeks before taking trial treatment), iii. vasectomised partner, iv. total sexual abstinence. Effective from the first administration of dabrafenib and trametinib (whichever is first), throughout the trial and for two weeks following discontinuation of dabrafenib and for 16 weeks following discontinuation of trametinib (whichever is later); Patients who are breastfeeding must be willing to discontinue breastfeeding from the start of treatment, throughout the trial and for two weeks following discontinuation of dabrafenib and for 16 weeks following discontinuation of trametinib (whichever is later)
  • Male patients with partners who are women of childbearing potential are eligible provided that they agree to the following, from the first administration of dabrafenib and trametinib (whichever is first), throughout the trial and for two weeks after the last administration of dabrafenib and 16 weeks after the last administration of trametinib (whichever is later):
  • Agree to take measures not to father children by using a barrier method of contraception (male condom plus spermicide) or to sexual abstinence
  • Non-vasectomised male partners with partners who are women of childbearing potential should also be advised of the benefit for their partner of using a highly effective method of contraception, such as:; combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation [oral, intravaginal or transdermal]), ii. progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), iii. IUD, iv. intrauterine hormone-releasing system (IUS), v. bilateral tubal occlusion, vi. total sexual abstinence
  • Male patients with pregnant or breastfeeding partners must be advised to use barrier method contraception (male condom) to prevent drug exposure of the foetus or neonate, even if vasectomised
  • Male patients must refrain from donating sperm for the same period
  • Patients must be able and willing to undergo a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patients with haematological malignancies or neuroblastomas, blood, bone marrow aspiration and/or trephine or lymph node biopsy samples may be taken
  • Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility

Who cannot take part

  • Previous treatment with dabrafenib and trametinib in combination (or other BRAF and MEK inhibitors in combination) for the current indication
  • Unstable angina within three months prior to screening
  • Myocardial infarction within three months prior to screening
  • History of documented congestive heart failure (New York Heart Association functional classification III/IV) etc; Patients with a cerebrovascular event (including stroke or transient ischaemic attack [TIA]) within three months prior to screening
  • Patients with primary central nervous system (CNS) tumours may be considered unless intratumoural bleeding has occurred within two weeks prior to the first dose of dabrafenib and trametinib, and patients with punctate CNS haemorrhages <3 mm may be considered
  • Patients who were administered a live, attenuated vaccine within 28 days prior to initiation of treatment, or anticipation of need for such a vaccine during investigational medicinal product (IMP) treatment or within six months after the final dose of dabrafenib and trametinib
  • Receiving antiretroviral therapy (ART) that does not interact with IMP (patients should be on established ART for at least four weeks); and
  • Any clinically significant concomitant disease or condition (or its treatment) that could interfere with the conduct of the trial (including absorption of oral medications) that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this trial
  • Diagnosis of one of the following BRAF V600E mutation-positive cancers:
  • Known hypersensitivity to dabrafenib or trametinib or any of the excipients. See the current relevant SmPCs (UK) for the full lists
  • Patients with a history of retinal vein occlusion
  • Any impairment of gastrointestinal (GI) function of uncontrolled GI disease that may significantly alter the administration or absorption of dabrafenib and/or trametinib (e.g. history of diverticulitis, metastases to the GI tract, uncontrolled Crohn's disease, uncontrolled ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome or short gut syndrome)
  • Clinically significant cardiac or cerebrovascular disease as defined by:
  • Known active infections (bacterial, fungal or viral) that would interfere with the assessment of safety or efficacy of dabrafenib and trametinib including human immunodeficiency virus (HIV) positivity. Patients with history of testing positive for HIV infection are eligible provided that each of the following conditions are met:
  • No HIV/acquired immune deficiency syndrome associated opportunistic infection in the last 12 months
  • CD4 count ≥350/µL
  • Colorectal cancer in adult (≥18 years) patients
  • Unresectable or metastatic melanoma in adult (≥18 years) patients
  • Advanced non-small cell lung cancer in adult (≥18 years) patients
  • Gliomas harbouring a BRAF V600E mutation in paediatric (1 to <16 years) or TYA (16 to <18 years) patients
  • Female patients who are pregnant, breastfeeding or planning to become pregnant during the trial or for two weeks following their last dose of dabrafenib or 16 weeks following their last dose of trametinib, whichever is later
  • Undetectable viral load

Other criteria

  • THE PATIENT MUST FULFIL THE ELIGIBILITY CRITERIA WITHIN THE DETERMINE MASTER PROTOCOL (NCT05722886) AND WITHIN THE TREATMENT ARM 07 (DABRAFENIB AND TRAMETINIB) OUTLINED BELOW* *When dabrafenib- and trametinib-specific inclusion/exclusion criteria or precautions below differ from those specified in the Master Protocol, the dabrafenib- and trametinib-specific criteria will take precedence

Where in United Kingdom

  • Belfast City HospitalBelfast, United KingdomContact: Vicky Coyle, ProfNot yet recruiting
  • Birmingham Children's HospitalBirmingham, United KingdomContact: Gerard Millen, DrNot yet recruiting
  • University Hospital BirminghamBirmingham, United KingdomContact: Gary Middleton, ProfNot yet recruiting
  • Bristol Haematology and Oncology CentreBristol, United KingdomContact: Antony Ng, DrNot yet recruiting
  • Bristol Royal Hospital for ChildrenBristol, United KingdomContact: Antony Ng, DrNot yet recruiting
  • Addenbrooke's HospitalCambridge, United KingdomContact: Bristi Basu, DrNot yet recruiting
  • Cardiff Children's HospitalCardiff, United KingdomContact: Madeline Adams, DrTaking people
  • Velindre Cancer CentreCardiff, United KingdomContact: Robert Jones, DrTaking people
  • Western General HospitalEdinburgh, United KingdomContact: Stefan Symeonides, DrTaking people
  • Royal Hospital for Children GlasgowGlasgow, United KingdomContact: Milind Ronghe, DrTaking people
  • The Beatson HospitalGlasgow, United KingdomContact: Patricia Roxburgh, DrNot yet recruiting
  • Leicester Royal InfirmaryLeicester, United KingdomContact: Harriet Walker, DrTaking people
  • Alder Hey HospitalLiverpool, United KingdomContact: Lisa Howell, DrNot yet recruiting
  • Great Ormond Street HospitalLondon, United KingdomContact: Darren Hargrave, DrNot yet recruiting
  • Guy's HopsitalLondon, United KingdomContact: James Spicer, DrTaking people
  • University College London HospitalLondon, United KingdomContact: Martin Foster, ProfTaking people
  • Royal Manchester Children's HospitalManchester, United KingdomContact: Guy Makin, DrNot yet recruiting
  • The Christie HospitalManchester, United KingdomContact: Matthew Krebs, ProfTaking people
  • Clatterbridge Cancer CentreMetropolitan Borough of Wirral, United KingdomContact: Dan Palmer, DrTaking people
  • Freeman HospitalNewcastle, United KingdomContact: Alastair Greystoke, DrTaking people
  • Great North Children's HospitalNewcastle, United KingdomContact: Alastair Greystoke, DrTaking people
  • Churchill HospitalOxford, United KingdomContact: Sarah Pratap, DrTaking people
  • John Radcliffe HospitalOxford, United KingdomContact: Sarah Pratap, DrTaking people
  • Sheffield's Children's HospitalSheffield, United KingdomContact: Daniel Yeomanson, DrNot yet recruiting
  • Weston Park HospitalSheffield, United KingdomContact: Sarah Danson, DrNot yet recruiting
  • Southampton General HospitalSouthampton, United KingdomContact: Juliet Gray, ProfTaking people
  • The Royal Marsden HospitalSutton, United KingdomContact: Lynley Marshall, DrTaking people

About the trial

What the trial wants to find out

This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in children with glioma (a type of brain tumour). This means they have gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Dabrafenib and trametinib work in patients with a particular mutation in their cancer known as BRAF V600.

Read full original descriptionShow less

Investigators now wish to find out if they will be useful in treating patients with other cancer types which have the same mutation. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.

This trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.

The group in the trial

  • Treatment Arm 07: Dabrafenib and TrametinibTreatment being tested

    This dabrafenib and trametinib treatment arm is for adult, paediatric and TYA patients with cancers harbouring BRAF V600 mutations.

    Treatment: Dabrafenib and Trametinib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and TYA Patients With BRAF V600 Mutation-Positive Cancers.
Plain-language title
Dabrafenib and trametinib for rare cancers with a BRAF V600 mutationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
17 August 2026